Originally posted by Jean
View Post
Unconfigured Ad
Collapse
X
-
yes,because 3 drafts already make up the marjority of the metagenomic data. I haven't map back the metagenomic raw reads yet.I have another question about this. I will calculate the coverage of each drafts to both metagenomic raw reads and metatranscriptomic raw data. I have made some pretreatments of metatranscriptomic data including removal of low quality(average Q-value<20 per reads) and removal of reads with number of unknow bases (N) >10.so I am wondering if I should deal with metagenomic raw data in the excatly same way? Thanks!
-
So you are only mapping to the "3 draft genomes" you got from the assembly and ignoring the rest? How much of your genomic data is represented in these drafts? If you map back the metagenomic reads how much coverage do you get and how much of your data is leftover?
Leave a comment:
-
Metatranscriptomic data(paired-end,Illumina)mapping?
We have sequenced metagenomic data and metatranscriptomic data by Hiseq2000 paired-end of acid mine drainage.
we run velvet to assemble the metagenomic data,and we succeeded to assemble 3 draft genomes(or bining sequences).
I would like to map the metatranscriptomic data to 3 drafts. I have tried with bowtie and soapaliner/soap2.
soap -a RNA_1.fasta -b RNA_2.fasta -D draft_geneome_ORFS_db.index -v 3 -r 2 -s 40 -m 400 -x 600 -o PE.out -2 SE.out
soap -a RNA_1.fasta -D draft_genome_ORFs_db.index -v 3 -r 2 -s 40 -o SE.out
but the results are both very poor,the mapping results are less than 1% .
while I use the total contigs of metagenomic data as reference,the mapping result can be 83%.
Does anyone know the methods to deal with my problems? Thanks a millon!
Latest Articles
Collapse
-
by SEQadmin2
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...-
Channel: Articles
10-14-2026, 09:55 AM -
-
by SEQadmin2
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...-
Channel: Articles
-
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, 10-15-2026, 10:52 AM
|
0 responses
23 views
0 reactions
|
Last Post
by SEQadmin2
10-15-2026, 10:52 AM
|
||
|
Started by SEQadmin2, 10-14-2026, 05:39 AM
|
0 responses
29 views
0 reactions
|
Last Post
by SEQadmin2
10-14-2026, 05:39 AM
|
||
|
Started by SEQadmin2, 10-13-2026, 09:56 AM
|
0 responses
25 views
0 reactions
|
Last Post
by SEQadmin2
10-13-2026, 09:56 AM
|
||
|
Started by SEQadmin2, 10-09-2026, 11:14 AM
|
0 responses
28 views
0 reactions
|
Last Post
by SEQadmin2
10-09-2026, 11:14 AM
|
Leave a comment: